Project No. 04

Modelling Prostate Cancer

Creating sophisticated, world-first models of advanced prostate cancer to accelerate drug development

S c r o l l   R i g h t

The Project

This project was launched as a result of Dr Williamson's work. It is creating sophisticated in-vivo models of advanced prostate cancer.

How?

The team is developing innovative, world-first models to test the effectiveness of new treatments for metastatic prostate cancer, to see if they are good enough and safe enough to be tested in humans.

What will this achieve?

The primary purpose of the models is to test the treatments being developed by other PCRC scientists. Better models of prostate cancer will also help us to better understand the disease.

The Future

The scientists will continue to develop in-vivo models of prostate cancer which will help to develop better therapies and get them into patients much faster.

The Project

This project was launched as a result of Dr Williamson's work. It is creating sophisticated in-vivo models of advanced prostate cancer.

How?

The team is developing innovative, world-first models to test the effectiveness of new treatments for metastatic prostate cancer, to see if they are good enough and safe enough to be tested in humans.

What will this achieve?

The primary purpose of the models is to test the treatments being developed by other PCRC scientists. Better models of prostate cancer will also help us to better understand the disease.

The Future

The scientists will continue to develop in-vivo models of prostate cancer which will help to develop better therapies and get them into patients much faster.

Project Start

October 2017

Research Facility

European Cancer Stem Cell Research Institute, Cardiff University

Budget

£87,000/year

End

October 2020

Impact

PCRC systematically monitors and evaluates the impact of our research using a set of metrics, or ‘Research Progress Indicators.’ They represent outcomes of research which is a catalyst for the development of new prostate cancer therapies. In the last 12 months, this project has achieved the following results.

Creating and Disseminating New Knowledge

Over the past 12 months, this group have published papers in highly respected journals including Cancer Discovery and the Journal of Pathology.

Growing Expertise

Professor Smalley is Scientific Chair of the Wales Cancer Partnership Translational Research Committee (TReC), a pool of expertise available to the South Wales cancer research community which is accessible to all researchers who hope to see their work transformed into a new clinical approach or therapy.

Scientific Progress

The Cardiff team have created and tested a number of models of the induction of prostate cancer. This work is very high quality and these models will provide important insights into the causes and development of prostate cancer, and strong validation of new, experimental interventions against prostate cancer.

Testing New Therapies

Boris and Matt have tested a batch of MPRCs from one of our other PCRC funded scientists, Aamir Ahmed, and found evidence to suggest that one in particular slows down the growth of prostate tumours in vivo. They are now finalising these tests, to determine which of these promising new drug candidates might work best.

They have also started to test PlexinB1 antibodies, from PCRC researcher Magali Williamson.

New Insights into Metastasis

The team have been working extensively to see what effects PlexinB1 has on cell migration, invasion and the spread of cancers in vivo, and how changes in some other genes can result in PlexinB1 having different effects on how prostate tumour cells spread. This information, which is highly complex, is reflective of how cancers can behave differently in different individuals, and will help to design more sophisticated therapies.

Prostate Cancer Cells and Energy Use

Boris and Matt are also trying to find out why prostate cancer cells need more energy to grow and divide than normal cells, and whether this requirement can be used against them by treatment with a drug normally used in treatment of Type II diabetes.

Help us fund a future for men and their families

As a small charity, we can focus the majority of our funds on research.

Support Us

Support the Modelling Prostate Cancer Project

Any donation you can make will help us fund this cutting-edge, life-saving research.

Press enter or esc to cancel